You have printed or saved this information from www.NATI.net, the website for the Newfoundland and Labrador Association of Technology Industries.
Sequence Bio Announces Major Precision Medicine Partnership with the Government of Newfoundland and Labrador
Posted Wednesday, October 14, 2015
(St. John's) - Sequence Bio, a privately held company located in Newfoundland and Labrador, has reached a partnership agreement with the Government of Newfoundland and Labrador. This partnership will focus on healthcare outcomes and supports Sequence Bio leadership work in commercial research and development opportunities in Newfoundland and Labrador.
"We are uniquely positioned to become a global player in this industry and are focused on ensuring families and patients in our province, together with their health care teams, have improved patient outcomes and enhanced care. Minister Kent and his team have worked hard to support Sequence Bio, as a local company growing in the global market and we appreciate their leadership and efforts in advancing better patient outcomes in this province.", notes Dr. Tyler Wish, Chief Executive Officer and founder of Sequence Bio.
Sequence Bio and the government want to work together to engage 100,000 voluntary, consenting participants in a large-scale initiative.
Minister Steve Kent, the Deputy Premier and Minister of Health and Community Services, says that, "Our government continues to explore opportunities to foster the development of a strong life sciences sector in the province, and this agreement is a step forward in positioning Newfoundland and Labrador as a world leader in precision medicine."
Founded by Dr. Tyler Wish and Chris Gardiner, Sequence Bio recently closed a $1,000,000 round of seed financing with an additional $500,000 investment from Killick Capital. In June/July of 2015, Pelorus Venture Capital and Klister Credit Corp. invested a total of $500,000.